Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study
European Journal of Neurology · 2024
DOI: 10.1111/ene.16450 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Luigi Francesco Iannone und 22 weiteren Autor:innen. Beteiligte Einrichtung: Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6‐month effectiveness and tolerability of anti‐CGRP mAbs in combination with other mAbs for different diseases.
Methods
Patients included in the Italian Headache Registry and treated concomitantly with an anti‐CGRP mAb and another mAb were included. Effectiveness outcomes for migraine included reduction from baseline of monthly headache days (MHDs), Migraine Disability Assessment (MIDAS) score, Headache Impact Test‐6 (HIT‐6) scores, and Patients' Global Impression of Change (PGIC) scale. Adverse events (AEs) were recorded.
Results
Thirty‐eight patients were included. In 27 patients (71.1%), the anti‐CGRP mAb was added to a previously ongoing mAb. Nine patients (23.7%) discontinued one of the two mAbs before the end of treatment (seven discontinued the anti‐CGRP mAb and two the other mAb). One patient discontinued for AEs. Anti‐CGRP mAbs were discontinued due to ineffectiveness ( n = 5, 55.5%) and one each (11.1%) for clinical remission and lost to follow‐up. MHDs significantly decreased from baseline to 3 months ( p < 0.0001) and 6 months ( p < 0.001), as did the MIDAS and the HIT‐6 scores at 3 and 6 months ( p < 0.001). For anti‐CGRP mAbs, 27.4% of patients reported PGIC ≥ 5 at 3 months and 48.3% at 6 months. Mild AEs associated with introduction of a second mAb were detected in six patients (15.8%).
Conclusions
In this real‐world study, anti‐CGRP mAbs showed safety and effectiveness when administered concomitantly with other mAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- Headache Center, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
ORCID-Profile: Marina Romozzi, Antonio Russo, Cristina Tassorelli, Maria Albanese
Zitieren
APA
Iannone, L. F., Romozzi, M., Russo, A., Saporito, G., De Santis, F., Ornello, R., Sances, G., Vaghi, G., Tassorelli, C., Albanese, M., Guerzoni, S., Casalena, A., Vollono, C., Calabresi, P., Prudenzano, M. P., Mampreso, E., Volta, G. D., Valente, M. R., Avino, G., …, & Italian Headache Registry (RICe) study group (2024). Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study. European Journal of Neurology. https://doi.org/10.1111/ene.16450
Vancouver
Iannone LF, Romozzi M, Russo A, Saporito G, De Santis F, Ornello R, et al. Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study. European Journal of Neurology. 2024. doi:10.1111/ene.16450
BibTeX
@article{Iannone2024,
author = {Iannone, Luigi Francesco and Romozzi, Marina and Russo, Antonio and Saporito, Gennaro and De Santis, Federico and Ornello, Raffaele and Sances, Grazia and Vaghi, Gloria and Tassorelli, Cristina and Albanese, Maria and Guerzoni, Simona and Casalena, Alfonsina and Vollono, Catello and Calabresi, Paolo and Prudenzano, Maria Pia and Mampreso, Edoardo and Volta, Giorgio Dalla and Valente, Maria Rosaria and Avino, Gianluca and Chiarugi, Alberto and Sacco, Simona and Pistoia, Francesca and Italian Headache Registry (RICe) study group, Italian Headache Registry (RICe) study group},
title = {Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16450}
}
EUVIMED